KPTI Overview

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Wall Street analysts forecast KPTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPTI is13.83 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Karyopharm Therapeutics Inc revenue for the last quarter amounts to 35.07M USD, increased 16.83

Karyopharm Therapeutics Inc. EPS for the last quarter amounts to -1.02 USD, decreased -63.18

Karyopharm Therapeutics Inc (KPTI) has 228 emplpoyees as of June 21 2026.

Today KPTI has the market capitalization of 204.42M USD.